AIHTA - Publications - Search - Gefitinib (Iressa®) for the first-line treatment of non-small cell lung cancer

Nachtnebel, A. (2010): Gefitinib (Iressa®) for the first-line treatment of non-small cell lung cancer . DSD: Horizon Scanning in Oncology 06.

[thumbnail of DSD_HSO_Nr.06.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
258kB
Abstract

Despite data indicating that patients suffering from non-small cell lung cancer with EGFR mutations might benefit from first-line therapy with gefitinib, several unresolved issues make it difficult to judge its final clinical value. Phase III studies were conducted in a population not representative for a Caucasian population and challenges remain in the determination of EGFR status.

Item Type:DSD: Horizon Scanning in Oncology
Keywords:non-small cell lung cancer, NSCLC, gefitinib, Iressa, oncology
Subjects:QZ Pathology > QZ 200-380 Neoplasms.Cysts
WF Respiratory system
Language:English
Series Name:DSD: Horizon Scanning in Oncology 06
Deposited on:28 Jan 2010 19:35
Last Modified:15 Jul 2020 17:43

Repository Staff Only: item control page